Rho-Associated Kinase Inhibitor Eye Drop (Ripasudil) Transiently Alters the Morphology of Corneal Endothelial Cells | Zendy

Naoki Okumura | Zendy; Yugo Okazaki | Zendy; Ryota Inoue | Zendy; Shinichiro Nakano | Zendy; Nigel J. Fullwood | Zendy; Shigeru Kinoshita | Zendy; Noriko Koizumi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rho-Associated Kinase Inhibitor Eye Drop (Ripasudil) Transiently Alters the Morphology of Corneal Endothelial Cells

Author(s) -

Naoki Okumura,

Yugo Okazaki,

Ryota Inoue,

Shinichiro Nakano,

Nigel J. Fullwood,

Shigeru Kinoshita,

Noriko Koizumi

Publication year - 2015

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.15-17887

Subject(s) - rho associated protein kinase , cornea , corneal endothelium , ophthalmology , chemistry , intraocular pressure , schlemm's canal , trabecular meshwork , microbiology and biotechnology , medicine , biology , kinase

Ripasudil (Glanatec), a selective Rho-associated coiled coil-containing protein kinase (ROCK) inhibitor, was approved in Japan in September 2014 for the treatment of glaucoma and ocular hypertension. The purpose of this study was to investigate the effect of ripasudil eye drops on corneal endothelial morphology, as ROCK signaling is known to modulate the actin cytoskeleton.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research